---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269833"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:33:59.990444+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sutro Biopharma Q3 revenue $9.7M, cash $167.6M; IND cleared for STRO-004

## Summary
- FDA cleared IND for STRO-004 (Tissue Factor ADC); first patient dosing expected before year-end.
- Cash, cash equivalents and marketable securities were $167.6M at Sept. 30, 2025, down from $388.3M a year earlier.
- Revenue was $9.7M (vs $8.5M Q3 2024), primarily from Astellas collaboration.
- R&D and G&A expenses totaled $48.6M, down from $76.4M in Q3 2024.
- Organizational restructuring expected to extend cash runway into at least mid-2027; restructuring costs estimated at $4.1M–$4.3M.

## SEC filing metadata
- accession: 0001193125-25-269833
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000119312525269833/0001193125-25-269833-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000119312525269833/stro-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269833
- JSON: https://secwatch.observer/filing/0001193125-25-269833.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269833.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.